Helomics helomics.com


Helomics is a comprehensive personalized healthcare company, aiming to bring the next generation of diagnostics to the oncology field. Helomics is dedicated to improving patient outcomes by providing a personalized comprehensive tumor profile utilizing a proprietary set of laboratory platforms that leverage both live and fixed cellular based analysis allowing physicians to characterize malignant tumors on a personalized basis. Helomics' novel molecular and cellular markers and bioinformatics ser...Show all

Helomics is a comprehensive personalized healthcare company, aiming to bring the next generation of diagnostics to the oncology field. Helomics is dedicated to improving patient outcomes by providing a personalized comprehensive tumor profile utilizi...Show all

Company (Acquired)

Phone: 412-432-1500

Fax:

91 43rd Street
Suite 220
Pittsburgh, 15201
Pennsylvania, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Helomics $215.1M Apr 23, 2018
See all 12 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Helomics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 17 investors

Competitors

Company Status Description Investors

NovoLogix

Eden Prairie, Minnesota, United States
AcquiredNovoLogix, formerly Ancillary Care Management, based in Eden Prairie, MN is a healthcare technology company delivering electronic claims re-pricing processes, prior authorization controls, and integrated patient care and pharmaceutical programs to assist its health plan customers in controlling their medical pharmacy spend.Login to see details

Micromet

Bethesda, Maryland, United States
AcquiredMicromet is focused on biological products for the treatment and control of cancer, inflammatory and autoimmune diseases. Using its antibody technology platforms, Micromet strives to create novel drugs that are highly specific, effective and well tolerated in patients. Its lead drug candidate is Adecatumumab (MT201), which offers a human antibody for treatment of solid tumors. In January 2012, Micromet was acquired by Amgen. The valuation of Micromet was $1.16 billion.Login to see details
See all 12 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Ex vivo liquid biopsy Mar 10, 2017 Application
Methods of simulating chemotherapy for a patient Nov 06, 2015 Application